Comparative Pharmacology
Head-to-head clinical analysis: CYPROHEPTADINE HYDROCHLORIDE versus PHYRAGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYPROHEPTADINE HYDROCHLORIDE versus PHYRAGO.
CYPROHEPTADINE HYDROCHLORIDE vs PHYRAGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyproheptadine is a potent antihistamine (H1 receptor antagonist) and antiserotonergic agent (5-HT2 receptor antagonist). It also exhibits weak anticholinergic and sedative properties. It blocks histamine-mediated vasodilation, increased capillary permeability, and pruritus, as well as serotonin-mediated effects on appetite and mood.
PHYRAGO is a monoclonal antibody that targets and neutralizes the activity of a specific inflammatory cytokine, thereby inhibiting downstream signaling pathways involved in immune-mediated inflammation.
4 mg orally three times daily; range 4-20 mg/day, not to exceed 0.5 mg/kg/day
200 mg orally twice daily with food.
None Documented
None Documented
Terminal half-life approximately 8–16 hours in adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life is 6–8 hours in adults; may be prolonged in hepatic impairment (up to 15 hours).
Primarily renal (appreciable unchanged drug and metabolites); biliary/fecal elimination minor (<5%).
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <5% of dose; fecal elimination of metabolites accounts for ~90%.
Category A/B
Category C
Antihistamine
Antihistamine